<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004394" GROUP_ID="DEMENTIA" ID="100702120915352808" MERGED_FROM="" MODIFIED="2008-11-07 13:15:12 +0100" MODIFIED_BY="Helen Collins" REVIEW_NO="" REVMAN_SUB_VERSION="5.0.16" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2008-11-07 13:15:12 +0100" MODIFIED_BY="Helen Collins">
<TITLE>Vitamin B12 for cognition</TITLE>
<CONTACT MODIFIED="2008-11-07 13:15:12 +0100" MODIFIED_BY="Helen Collins"><PERSON ID="13050" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Reem</FIRST_NAME><LAST_NAME>Malouf</LAST_NAME><POSITION>Systematic Reviewer and Clinical Trials Coding Specialist</POSITION><EMAIL_1>reemmalouf@yahoo.com</EMAIL_1><ADDRESS><ORGANISATION>Cochrane Dementia and Cognitive Improvement Group</ORGANISATION><ADDRESS_1>John Radcliffe Hospital (4th Floor, Room 4401C)</ADDRESS_1><ADDRESS_2>Headington</ADDRESS_2><CITY>Oxford</CITY><ZIP>OX3 9DU</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>01865 234306</PHONE_1><FAX_1>01865 221354</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-11-07 13:15:12 +0100" MODIFIED_BY="Helen Collins"><PERSON ID="13050" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Reem</FIRST_NAME><LAST_NAME>Malouf</LAST_NAME><POSITION>Systematic Reviewer and Clinical Trials Coding Specialist</POSITION><EMAIL_1>reemmalouf@yahoo.com</EMAIL_1><ADDRESS><ORGANISATION>Cochrane Dementia and Cognitive Improvement Group</ORGANISATION><ADDRESS_1>John Radcliffe Hospital (4th Floor, Room 4401C)</ADDRESS_1><ADDRESS_2>Headington</ADDRESS_2><CITY>Oxford</CITY><ZIP>OX3 9DU</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>01865 234306</PHONE_1><FAX_1>01865 221354</FAX_1></ADDRESS></PERSON><PERSON ID="12995" ROLE="AUTHOR"><FIRST_NAME>Almudena</FIRST_NAME><LAST_NAME>Areosa Sastre</LAST_NAME><POSITION>Geriatrician</POSITION><EMAIL_1>almudenaareosa@hotmail.com</EMAIL_1><ADDRESS><ORGANISATION/><ADDRESS_1>c/ Mauricio Legendre 17, 5-A</ADDRESS_1><CITY>Madrid</CITY><ZIP>28046</ZIP><COUNTRY CODE="ES">Spain</COUNTRY><PHONE_1>+34 913152686</PHONE_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-11-07 11:55:40 +0000" MODIFIED_BY="Helen Collins">
<UP_TO_DATE>
<DATE DAY="24" MONTH="1" YEAR="2006"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="24" MONTH="1" YEAR="2006"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="23" MONTH="1" YEAR="2009"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="" YEAR=""/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2003"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2003"/>
</DATES>
<WHATS_NEW MODIFIED="2008-11-07 11:53:54 +0000" MODIFIED_BY="Helen Collins">
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="7" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-11-07 11:54:02 +0000" MODIFIED_BY="Helen Collins">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-11-07 11:54:02 +0000" MODIFIED_BY="Helen Collins">
<DATE DAY="23" MONTH="5" YEAR="2006"/>
<DESCRIPTION>
<P>Update 2006: One randomized double-blind controlled trial (Hvas 2004) was found in the new search. This trial was performed on elderly with cognitive impairment and vitamin B12 deficiency. No data was available at the end of the treatment period, however, the follow-up results at three months did not show any efficacy of B12 treatment on cognitive function.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="25" MONTH="5" YEAR="2003"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Division of Clinical Geratology, Nuffield Department of Clinical Medicine, University of Oxford</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>NHS R&amp;D</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-11-07 11:57:21 +0000" MODIFIED_BY="Helen Collins">
<SUMMARY MODIFIED="2008-11-07 11:54:42 +0000" MODIFIED_BY="Helen Collins">
<TITLE MODIFIED="2008-11-07 11:54:42 +0000" MODIFIED_BY="Helen Collins">No evidence of the efficacy of vitamin B12 supplementation for cognitive function</TITLE>
<SUMMARY_BODY>
<P>Vitamin B12 is essential for maintaining normal function of the nervous system, but the relationship between vitamin B12 and cognitive function is not fully understood. From the three studies involving people with dementia or cognitive impairment and low blood levels of vitamin B12 eligible for inclusion in this review there was no statistically significant effect of vitamin B12 supplementation on cognition. The variety of measurement scales used to assess outcomes and uncertainty about diagnostic criteria for vitamin B12 deficiency create difficulties in pooling the results of trials.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>An association between neuropsychiatric disorders and vitamin B12 deficiency has been recognized since 1849 when pernicious anaemia was first described. It has been suggested that deficiency of vitamin B12 might contribute to age-associated cognitive impairment. Low serum vitamin B12 concentrations are found in more than 10% of older people. A high prevalence of low serum vitamin B12 levels, and other indicators of vitamin B12 deficiency have been reported among people with Alzheimer's disease. A review is needed of trials assessing effects of vitamin B12 supplementation on cognitive function in later life. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To examine the effect of B12 supplementation on cognitive function of demented and elderly healthy people in terms of preventing the onset or progression of cognitive impairment or dementia. </P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>The trials were identified from a search of the Specialized Register of the Cochrane Dementia and Cognitive Improvement Group on 24 January 2006 using the terms B12, "B 12", B-12, B-complex, "B complex". In addition MEDLINE 1966 to 2006/01-week 3 and EMBASE 1980-2005/12 were searched to pick up studies with healthy volunteers.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>All randomized double-blind trials in which vitamin B12 at any dose was compared with placebo. </P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Both reviewers applied the selection criteria to assess the quality of the studies. One reviewer (RM) collated and analysed the data. For each outcome measure data were sought on every patient randomized. </P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Three trials were included (De La Fourniere 1997; Hvas 2004; Seal 2002). One trial (Hvas 2004) reported follow-up results at 3 months after randomization, 2 months after treatment was completed; the data from this study were not combined with others. People with dementia and low serum vitamin B12 levels were recruited for the studies. The results showed no statistically significant evidence of a treatment effect of vitamin B12 supplementation compared with placebo, on cognitive function. </P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Evidence of any efficacy of vitamin B12 in improving the cognitive function of people with dementia and low serum B12 levels is insufficient. The included trials (De La Fourniere 1997; Hvas 2004; Seal 2002) were restricted to a small number of patients with Alzheimer's disease and other types of cognitive impairment. No trials involving people without dementia or using other definitions of vitamin B12 deficiency were found.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-11-07 11:57:21 +0000" MODIFIED_BY="Helen Collins">
<BACKGROUND MODIFIED="2008-11-07 11:55:14 +0000" MODIFIED_BY="Helen Collins">
<P>Vitamin B12 is a water-soluble vitamin that is non-toxic in humans, although associated in very high doses with the production of amnesia in chicks (<LINK REF="REF-Crowe-1997" TYPE="REFERENCE">Crowe 1997</LINK>). Humans are dependent on animal-origin sources to obtain their requirement of B12 from the diet. Although this vitamin is synthesized in the human large bowel by micro-organisms in considerable quantities, it is not absorbed from this site. The recommended daily requirement for adults is 2-5 microgram, and the average adult daily intake from an unrestricted diet is 5-30 microgram, with around 10 to 30% being destroyed by cooking. The body storage of B12, mainly in the liver, is 2-5 mg (<LINK REF="REF-Firkin-1989" TYPE="REFERENCE">Firkin 1989</LINK>). Vegans are the only population group at risk of developing dietary B12 deficiency (<LINK REF="REF-Herbert-1996" TYPE="REFERENCE">Herbert 1996</LINK>), but as the absorption of the vitamin may decline with age, the Food Protection Program recommended that older people attain their need of this vitamin from supplements or fortified foods (<LINK REF="REF-Kwan-2002" TYPE="REFERENCE">Kwan 2002</LINK>). </P>
<P>The absorption of dietary vitamin B12 requires its release from food by gastric acid, the formation of a complex with R-proteins and linkage to intrinsic factor secreted by the stomach. After absorption in the lower small intestine vitamin B12 is transferred to its utilization sites by three carriers, transcobalamin I, II and III. The two active forms of the vitamin are adenosylcobalamin, a major form in the cellular tissues, and methylcobalamin predominating in the plasma. Older people are at risk of developing vitamin B12 deficiency because of loss of intrinsic factor (in Addisonian pernicious anaemia) or through decreased secretion of the gastric acid necessary to release the vitamin from food. Reduction of gastric acid in later life may arise through inflammation of the stomach or from drugs given to combat peptic ulcer, oesophageal regurgitation or dyspepsia. In one survey, although pernicious anaemia was responsible for 50% of the causes of B12 deficiency, it only accounted for 10% of older people with low serum levels of vitamin B12 (<LINK REF="REF-Metz-1996" TYPE="REFERENCE">Metz 1996</LINK>). </P>
<P>The two therapeutic forms are cyanocobalamin and hydroxocobalamin, usually given by injection and there is no interference with the actions of other drugs. The absorption of dietary vitamin B12 can be impaired by some medications, such as anti-convulsants, alcohol, potassium products, cimetidine, ranitidine, aminosaliycylic acid and proton pump inhibitors. </P>
<P>Vitamin B12 is required for the methylation of homocysteine (Hcy) to methionine, which is activated into S-adenosyl-methionine that donates its methyl group (CH3) to methyl acceptors such as myelin, neurotransmitters, and membrane phospholipids, essential for maintaining the integrity of the nervous and haematopoietic systems (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). Insufficiency of vitamin B12 causes disruption of this cycle and intracellular accumulation of homocysteine that is potentially toxic to neurons. Blood levels of homocysteine are also raised by metabolically significant vitamin B12 deficiency. Raised blood levels of homocysteine are a risk factor for vascular disease (<LINK REF="REF-Clarke-1991" TYPE="REFERENCE">Clarke 1991</LINK>) and a predictive marker for cognitive decline in healthy older people (<LINK REF="REF-McCaddon-2001" TYPE="REFERENCE">McCaddon 2001</LINK>). Elevated serum homocysteine levels are frequently found in healthy older people ( <LINK REF="REF-Joosten-1997" TYPE="REFERENCE">Joosten 1997</LINK>), and vitamin B12 deficiency is suggested as a major cause of elevated homocysteine in elderly populations (<LINK REF="REF-Stabler-1997" TYPE="REFERENCE">Stabler 1997</LINK>). </P>
<P>Low serum B12 levels are found in 10 to 15% of people aged over 60 years (<LINK REF="REF-Elsborg-1976" TYPE="REFERENCE">Elsborg 1976</LINK>; <LINK REF="REF-Elwood-1971" TYPE="REFERENCE">Elwood 1971</LINK>; <LINK REF="REF-Gaffney-1957" TYPE="REFERENCE">Gaffney 1957</LINK>; <LINK REF="REF-Kilpatrick-1965" TYPE="REFERENCE">Kilpatrick 1965</LINK>). The prevalence varies with sex and ethnic group; the frequency of low serum B12 is higher in Europe than in the United States (<LINK REF="REF-Lindenbaum-1994" TYPE="REFERENCE">Lindenbaum 1994</LINK>; <LINK REF="REF-Pennypacker-1992" TYPE="REFERENCE">Pennypacker 1992</LINK>; <LINK REF="REF-Van-Asselt--1998" TYPE="REFERENCE">Van Asselt 1998</LINK>), and elderly men are more likely to have low serum B12 than are elderly women. Low serum levels do not however necessarily indicate metabolically significant deficiency of vitamin B12. Not all the vitamin circulating in the blood is in metabolically active form and blood levels do not necessarily reflect intracellular conditions. Criteria for metabolically significant deficiency vary and estimates of its prevalence in older populations vary from 3.0 to 40.5% (<LINK REF="REF-Baik-1999" TYPE="REFERENCE">Baik 1999</LINK>). </P>
<P>Most studies prior to 1980 relied on serum vitamin B12 determinations and absorption tests to identify vitamin B12 deficiency. However, subnormal serum cobalamin levels are not specific for cobalamin deficiency (<LINK REF="REF-Stabler-1990" TYPE="REFERENCE">Stabler 1990</LINK>) and serum and tissue vitamin B12 are insensitive screening tests. In one study, tissue vitamin deficiency was present in only 88% of 94 elderly people with serum vitamin levels &lt;150 pmol/L (<LINK REF="REF-Metz-1996" TYPE="REFERENCE">Metz 1996</LINK>). Recently, measuring serum levels of methylmalonic acid (MMA) or total homocysteine (tHcy) have been found useful as biochemical markers of cobalamin deficiency in people with minor or no haematological abnormalities (<LINK REF="REF-Marcell-1985" TYPE="REFERENCE">Marcell 1985</LINK>; <LINK REF="REF-Stabler-1986" TYPE="REFERENCE">Stabler 1986</LINK>). In a study of 152 geriatrics outpatients, the prevalence of vitamin B12 deficiency defined by serum B12 level &lt;300pg/ml and levels of (tHcy) elevated to &gt;3 SD, was 14.5% (<LINK REF="REF-Pennypacker-1992" TYPE="REFERENCE">Pennypacker 1992</LINK>). In addition, MMA and/or tHcy levels were shown to be necessary in evaluating the benefit of the treatment in terms of low or low-normal cobalamin blood levels (<LINK REF="REF-Pennypacker-1992" TYPE="REFERENCE">Pennypacker 1992</LINK>). The conventional lower limit for serum vitamin B12 is 150 pg/ml, but <LINK REF="REF-Lindenbaum-1994" TYPE="REFERENCE">Lindenbaum 1994</LINK> reported that deficiency should be suspected when the serum level declines below 300 pg/mL in older people. In summary, accurate diagnosis of vitamin B12 deficiency remains controversial, but low plasma cobalamin concentrations do not necessarily indicate significant deficiency and normal levels do not necessarily exclude it. </P>
<P>Severe vitamin B12 deficiency manifests clinically as a syndrome involving the nervous and/or the haematopoietic systems. It can present with anaemia, polyneuropathy (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>), subacute combined degeneration of the spinal cord (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>), and various neuropsychiatric problems including cognitive impairment and dementia. The majority of older people with low serum levels of vitamin B12, have no clinical features of deficiency (<LINK REF="REF-Matcher-1994" TYPE="REFERENCE">Matcher 1994</LINK>), although half of them have metabolically significant deficiency (<LINK REF="REF-Lindenbaum-1994" TYPE="REFERENCE">Lindenbaum 1994</LINK>). Neuropsychiatric disorders, in the absence of haematological or metabolical changes, are common features of deficiency in older people. <LINK REF="REF-Lindenbaum-1994" TYPE="REFERENCE">Lindenbaum 1994</LINK> found that 40 patients out of 141 with vitamin B12 deficiency exhibited neuropsychiatric abnormalities without anaemia. Associations between vitamin B12 status and cognitive performance in both healthy and impaired people have been reported (<LINK REF="REF-Goodwin-1983" TYPE="REFERENCE">Goodwin 1983</LINK>; <LINK REF="REF-La-Rue-1997" TYPE="REFERENCE">La Rue 1997</LINK>; <LINK REF="REF-Riggs-1996" TYPE="REFERENCE">Riggs 1996</LINK>). It has been found that patients with low vitamin B12 levels are at enhanced risk of cerebrovascular disease and cognitive decline (<LINK REF="REF-Shahar-2001" TYPE="REFERENCE">Shahar 2001</LINK>). Poorer memory performance by normal elderly people with low vitamin B12 concentrations has been reported (<LINK REF="REF-Goodwin-1983" TYPE="REFERENCE">Goodwin 1983</LINK>). Such correlations between vitamin B12 and cognition emphasize the need to clarify the role of the vitamin in dementia. </P>
<P>It has been reported that 15% of people with dementia have a potentially treatable cause (<LINK REF="REF-Marsden-1972" TYPE="REFERENCE">Marsden 1972</LINK>), but the prevalence of reversible dementia is only 1% (<LINK REF="REF-Walstra-1997" TYPE="REFERENCE">Walstra 1997</LINK>) and vitamin B12 deficiency contributes to only 1% of reversible cases (<LINK REF="REF-Clarfield-1988" TYPE="REFERENCE">Clarfield 1988</LINK>). None the less, the association of vitamin B12 with cognitive impairment makes assay of blood levels a recommended routine investigation in dementia (<LINK REF="REF-Wivel-1988" TYPE="REFERENCE">Wivel 1988</LINK>). Dementia is common in later life, affecting 10% of people aged over 65 with a prevalence rising to 20% of people over 80 (<LINK REF="REF-Jorm-1990" TYPE="REFERENCE">Jorm 1990</LINK>). Alzheimer's disease (AD) accounts for more than 70% of cases of dementia, so it is important to identify risk factors for this disease. The prevalence of low serum vitamin B12 levels has been reported to be significantly higher in people with Alzheimer's disease than in people with other types of dementia (<LINK REF="REF-Tripathi-2001" TYPE="REFERENCE">Tripathi 2001</LINK>). It has also been found that serum tHcy levels in patients with Alzheimer's dementia are significantly higher and serum vitamin B12 concentrations significantly lower than in controls (<LINK REF="REF-Clarke-1998" TYPE="REFERENCE">Clarke 1998</LINK>; <LINK REF="REF-McCaddon-2001" TYPE="REFERENCE">McCaddon 2001</LINK>). </P>
<P>Several hypotheses have been advanced to explain the high frequency of low vitamin B12 levels in demented older people. Poor diet is one suggestion, but its effects would be unlikely to become apparent in less than one or two decades, given the very low daily intake required and the body storage of the vitamin. Transcobalamin II, responsible for the carriage of 15% to 20% of vitamin B12, has been reported to be low in old age. This raises the possibility of an age-associated defect of cobalamin delivery into the tissues (<LINK REF="REF-Marcus-1987" TYPE="REFERENCE">Marcus 1987</LINK>). Low vitamin B12 levels in elderly and demented people might be due to malabsorption consequent on the atrophic gastritis with hypochlorhydria (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>) common among older people. Another hypothesis is that patients with Alzheimer's disease have inactive analogue forms of vitamin B12 in their serum (<LINK REF="REF-McCaddon-2001" TYPE="REFERENCE">McCaddon 2001</LINK>). It has been suggested that one-carbon metabolism, in which vitamin B12 is involved, might be compromised by deposition of amyloid, one of the characteristic features of Alzheimer's disease (<LINK REF="REF-Regland-1999" TYPE="REFERENCE">Regland 1999</LINK>). Another hypothesis is that Alzheimer's disease may cause dysfunction in the ability to use vitamin B12 by affecting cellular function so as to reduce vitamin B12 absorption, storage, utilization and or excretion (<LINK REF="REF-Levitt-1992" TYPE="REFERENCE">Levitt 1992</LINK>). </P>
<P>Some intervention studies examined the relationship between the vitamin status and the cognitive function on healthy and demented people. One study of cognitively unimpaired community-dwelling old people with low serum vitamin B12 levels measured cognitive and cerebral function before and after supplementation with vitamin B12. There were improvements in function and the increase in scores on a verbal word learning test were substantial (<LINK REF="REF-van-Asselt-2001" TYPE="REFERENCE">van Asselt 2001</LINK>).</P>
<P>Several observational, non-randomized or confounded studies of effects of vitamin B12 on people with dementia have been published. Despite suggestions that supplementation may improve language and frontal lobe function in patients with cognitive impairment and low serum vitamin B12 level, no changes were found in the MMSE (<LINK REF="STD-Eastley-2000" TYPE="STUDY">Eastley 2000</LINK>). <LINK REF="REF-Ikeda-1992" TYPE="REFERENCE">Ikeda 1992</LINK> reported a correlation between cognitive function and the levels of vitamin B12 in the cerebrospinal fluid in Alzheimer's patients treated with intravenous vitamin B12. <LINK REF="REF-Carmel-1995" TYPE="REFERENCE">Carmel 1995</LINK> observed improvements in blood homocysteine and haemoglobin levels, neuropsychiatric symptoms, electroencephalographic abnormalities in 13 patients with Alzheimer's disease and low serum B12 after supplementation, but there was no improvement in cognitive function. <LINK REF="STD-Takao-2001" TYPE="STUDY">Takao 2001</LINK>has reported that bright light therapy accompanied by vitamin B12 supplementation improved circadian rhythm disturbances and cognitive state of patients in the early stages of Alzheimer's disease. </P>
<P>Other studies have found no benefit from vitamin B12 supplementation in terms of cognitive function or delay in deterioration for patients with dementia and low serum vitamin B12 levels when assessed against a matching group (<LINK REF="STD-Eastley-2000" TYPE="STUDY">Eastley 2000</LINK>). Teunisse 1996a found no effect over six months of vitamin B12 supplementation on the severity of cognitive decline in a comparison of treated and untreated groups of people with Alzheimer's disease. <LINK REF="REF-Levitt-1992" TYPE="REFERENCE">Levitt 1992</LINK> described two patients with Alzheimer's disease and low serum vitamin B12 levels whose cognitive performance continued to decline despite their serum vitamin B12 levels returning to normal after supplementation. Observing a group of people with vitamin B12 deficiency without measurement of cognitive function, <LINK REF="STD-Hughes-1970" TYPE="STUDY">Hughes 1970</LINK> concluded that vitamin B12 replacement therapy was no better than placebo in terms of responses to a self -report questionnaire and psychiatric assessment. <LINK REF="STD-Nagga-2002" TYPE="STUDY">Nagga 2002</LINK> observed the effect of a year of cobalamin supplementation on 23 patients with cognitive impairment and newly diagnosed cobalamin deficiency. There was no beneficial effect from cobalamin supplementation on cognition or on electroencephalography (EEG); 14 patients deteriorated in their MMSE scores and 17 showed an increase in EEG abnormalities. It has been suggested that there is a time-limited window of less than one year during which vitamin B12 treatment is effective for patients with cognitive impairment and with low serum vitamin B12 (<LINK REF="STD-Abyad-2002" TYPE="STUDY">Abyad 2002</LINK>; <LINK REF="STD-Martin-1992" TYPE="STUDY">Martin 1992</LINK>). If this is so, early detection and treatment will be essential to the reversibility of cognitive impairment attributable to vitamin B12 deficiency.</P>
<P>Some researchers have challenged the existence of a reversible dementia due to vitamin B12 deficiency (<LINK REF="REF-Byrne-1987" TYPE="REFERENCE">Byrne 1987</LINK>; <LINK REF="REF-Hector-1988" TYPE="REFERENCE">Hector 1988</LINK>), and few cases of reversible dementia attributed to deficiency of vitamin B12 have been reported in the literature in which supplementation has produced complete recovery. In one series of 18 patients with vitamin B12 deficiency and cognitive impairment, eight with global dementia, eleven patients showed complete recovery after vitamin B12 replacement (<LINK REF="REF-Healton-1991" TYPE="REFERENCE">Healton 1991</LINK>). The Synonym Learning tests returned to normal in 9 of 12 patients with pernicious anaemia after treatment, the earliest changes were observed 20 hours from the intervention (<LINK REF="REF-Shulman-1967" TYPE="REFERENCE">Shulman 1967</LINK>). Among 152 moderately to severely demented patients who met criteria of global cognitive impairment, one patient had dementia attributed to vitamin B12 deficiency, but the duration of the disease and the result of treatment were not reported (<LINK REF="REF-Erkinjuntti-1986" TYPE="REFERENCE">Erkinjuntti 1986</LINK>). The vitamin B12 replacement therapy was associated with temporary improvement in cognitive performance in two patients with Alzheimer's disease and low serum vitamin B12 levels, but there was no benefit observable in a one-year follow-up evaluation (<LINK REF="REF-Larson-1985" TYPE="REFERENCE">Larson 1985</LINK>). However, in some of these cases (<LINK REF="REF-Healton-1991" TYPE="REFERENCE">Healton 1991</LINK>; <LINK REF="REF-Larson-1985" TYPE="REFERENCE">Larson 1985</LINK>) there was no neuropsychiatric assessment or use of standardized diagnostic criteria for dementia. </P>
<P>It is necessary to know whether low vitamin B12 levels are a cause or a consequence of Alzheimer's disease. Untreated deficiency in asymptomatic old people might cause impairment of cognitive function that becomes irreversible (<LINK REF="STD-Martin-1992" TYPE="STUDY">Martin 1992</LINK>). Conversely, people with Alzheimer's disease and low vitamin B12 levels may be more severely demented and have suffered from dementia and reduced nutrition for a longer time than patients with normal serum levels (<LINK REF="REF-Meins-2000" TYPE="REFERENCE">Meins 2000</LINK>). </P>
<P>In considering the significance of vitamin B12 deficiency in later life, a central concern is how deficiency should be defined. Traditionally, the necessary intake of a vitamin is determined with regard to preventing the deficiency disease specific to lack of the vitamin. Until recently the specific deficiency disease for vitamin B12 has been pernicious anaemia; should hyperhomocysteinaemia, where not due to folic acid deficiency or renal failure, now be regarded as indicating mild or incipient vitamin B12 deficiency? The issue has ethical implications for the design of controlled trials; it would not be ethical to leave people with pernicious anaemia or subacute combined degneration of the spinal cord untreated in a control group, would it now be unethical for people with high homocysteine levels to be allocated to a control group? One issue is that the original evidence for a relationship between homocysteine and vascular disease and dementia was derived from observational studies; whether the relationship is causative can only be resolved by intervention studies. There also remains a possibility that vitamin B12 has benefits for brain function not mediated through homocysteine metabolism. Clearly, the ethical situation will change as science advances.</P>
<P>Therefore, the central question is whether degrees of vitamin B12 deficiency insufficient to manifest as megaloblastic anaemia or neurological disorder cause cognitive impairment and dementia, the answer may depend on how vitamin B12 deficiency is defined. In the absence of overt neurological signs it may be defined simply in terms of low blood levels of vitamin B12, or as low blood levels of vitamin B12 plus evidence of metabolically significant deficiency in the form of raised blood homocysteine or methlymalonic acid. <BR/>A third possibility, arising in a public health context, is whether giving vitamin B12 to people without knowledge of their blood biochemistry will reduce the incidence or severity of cognitive impairment and dementia in a population.<BR/> <BR/>In this review of vitamin B12 as a possible means for preventing or retarding the progression of cognitive impairment in healthy people and in people with dementia, particular attention needs to be paid to the eligibility criteria for participants in trials in order to determine which of the these situations in being investigated. </P>
</BACKGROUND>
<OBJECTIVES>
<P>To estimate the effect of vitamin B12 on cognitive function of healthy elderly people and of people with dementia. </P>
</OBJECTIVES>
<METHODS MODIFIED="2008-11-07 11:57:21 +0000" MODIFIED_BY="Helen Collins">
<SELECTION_CRITERIA MODIFIED="2008-11-07 11:57:21 +0000" MODIFIED_BY="Helen Collins">
<CRIT_STUDIES MODIFIED="2008-11-07 11:57:21 +0000" MODIFIED_BY="Helen Collins">
<P>The review aims to include all randomized placebo-controlled double-blind trials of the effects of vitamin B12 on cognitive function at any dose or by any route of administration. Trials in which combinations of folic acid and B12 were administrated were excluded, as they are the subject of another Cochrane review (<LINK REF="REF-Malouf-2003a" TYPE="REFERENCE">Malouf 2003a</LINK>). The review also discusses case-control studies of the relationship between vitamin B12 and cognitive impairment or dementia. </P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Elderly healthy people and patients at any stage or type of cognitive impairment with or without vitamin B12 deficiency as defined by the trialists. </P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Vitamin B12 at any dosage or route of administration compared with placebo. </P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>Cognitive function measures. </P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P>Trials were identified from a search of the Specialized Register of the Cochrane Dementia and Cognitive Improvement Group on 24 January 2006 using the terms using the terms B12, "B 12", B-12, B-complex, "B complex" </P>
<P>The Specialized Register at that time contained records from the following databases:<BR/>
</P>
<UL>
<LI>CENTRAL: July 2005 (issue 3);</LI>
<LI>MEDLINE: 1966 to 2005/08, week 2;</LI>
<LI>EMBASE: 1980 to 2005/08, week 2;</LI>
<LI>PsycINFO: 1887 to 2005/07;</LI>
<LI>CINAHL: 1982 to 2004/07;</LI>
<LI>SIGLE (Grey Literature in Europe): 1980 to 2004/06;</LI>
<LI>ISTP (Index to Scientific and Technical Proceedings): to May 2000;</LI>
<LI>INSIDE (BL database of Conference Proceedings and Journals): to June 2000;</LI>
<LI>Aslib Index to Theses (UK and Ireland theses): 1970 to March 2003;</LI>
<LI>Dissertation Abstract (USA): 1861 to March 2003;</LI>
<LI>http://clinicalstudies.info.nih.gov/;</LI>
<LI>National Research Register (issue 3/2005);</LI>
<LI>ClinicalTrials.gov: last searched 1 January 2006;</LI>
<LI>LILACS: Latin American and Caribbean Health Science Literature: last searched April 2003;</LI>
<LI>http://www.forestclinicaltrials.com/: last searched 1 September 2005;</LI>
<LI>ClinicalStudyResults.org: last searched 1 September 2005;</LI>
<LI>http://www.lillytrials.com/index.shtml: last searched 28 August 2005;</LI>
<LI>ISRCTN Register: last searched 1 September 2005;</LI>
<LI>IPFMA Clinical trials Register: www.ifpma.org/clinicaltrials.html: last searched September 2005.</LI>
</UL>
<P>
<BR/>The search strategies used to identify relevant records in MEDLINE, EMBASE, PsycINFO, CINAHL and LILACS can be found in the Group's module.<BR/>
<BR/>MEDLINE 1966 to 2006/01-week 3 and EMBASE 1980-2005/12 were searched using the same terms to pick up studies with healthy volunteers. The following search strategies were used:</P>
<P>MEDLINE:<BR/> #1 B12 or "B 12" or B-12 or B-complex or "B complex" <BR/> #2 explode "Vitamin-B-12"/ all subheadings <BR/> #3 #1 or #2 <BR/> #4 random* or placebo* or "double blind*" or double-blind* <BR/> #5 #3 and #4 <BR/> #6 #5 and (cognit* or MMSE or ADAS-cog) </P>
<P>EMBASE:<BR/> #1 "cyanocobalamin"/ all subheadings <BR/> #2 B12 or "B 12" or B-12 or B-complex or "B complex" <BR/> #3 5#1 or #2 <BR/> #4 random* or placebo* or "double blind*" or double-blind* <BR/> #5 #3 and #4 <BR/> #6 #5 and (cognit* or MMSE or ADAS-cog)</P>
<P>The internet was searched using the super search engine Copernic using the term "B12 cognition trial".</P>
<P>Reference lists of retrieved articles were examined for additional trials. Books concerning vitamin B12 and cognition were handsearched for additional trials. </P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>SELECTION OF STUDIES<BR/>Abstracts of the references retrieved by the search were read by one reviewer who discarded those that were clearly not eligible for inclusion. Both reviewers studied the full text of the remaining references and independently selected studies for inclusion. Any disparities were resolved by discussion to arrive at a final list of included studies. </P>
<P>QUALITY ASSESSMENT<BR/>The reviewers (RM and AAS) assessed the methodological quality of each trial using Cochrane Collaboration guidelines (<LINK REF="REF-Mulrow-1997" TYPE="REFERENCE">Mulrow 1997</LINK>):<BR/>
</P>
<UL>
<LI>In category A (adequate), the report describes allocation of treatment by: (i) some forms of centralized randomized scheme, such as having to provide details of an enrolled participant to an office by telephone to receive the treatment group allocation; (ii) some form of randomization scheme controlled by a pharmacy; (iii) numbered or coded containers, as in a pharmaceutical trial in which capsules from identical-looking numbered bottles are administrated sequentially to enrolled participants; (iv) an on-site or coded computer system, provided that the allocations were in a locked, unreadable file that could be accessed only after inputting the characteristics of an enrolled participants; or (v) if assignment envelopes were used, the report should at least specify that they were sequentially numbered, sealed, and opaque; (vi) other combinations of described elements of the process that provide assurance of adequate concealment. </LI>
</UL>
<P>
<BR/>
</P>
<UL>
<LI>For Category B (intermediate) the report describes allocation of treatment by: (i) use of a ''list'' of ''table'' to allocate assignments; (ii) use of ''envelopes'' or ''sealed envelopes''; (iii) stating the study as ''randomized'' without further detail. </LI>
</UL>
<P>
<BR/>
</P>
<UL>
<LI>In Category C (inadequate) reports describe allocation of treatment by: (i) alternation; (ii) reference to case record numbers, dates of birth, day of week, or any such approach; (iii) any allocation procedure that is transparent before assignment, such as an open list of random numbers or assignments. Empirical research has shown that lack of adequate allocation concealment is associated with bias. Trials with unclear concealment measures have been shown liable to yield more pronounced estimates of treatment effects than trials that have adequate measure to conceal allocation schedules, but the effect is less pronounced than inadequately concealed trials (<LINK REF="REF-Chalmers-1983" TYPE="REFERENCE">Chalmers 1983</LINK>; <LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>). Trials are to be considered if they conform to categories A or B, but those falling in category C are excluded. Other aspects of trial quality were not assessed by a scoring system but details of blinding, appropriateness of methods and the number of patients lost to follow-up were to be be noted. </LI>
</UL>
<P>
<BR/>DATA COLLECTION <BR/>Data were extracted from the published reports. The summary statistics required for each trial and each outcome for continuous data were the mean change from baseline, the standard error of the mean change, and the number of patients for each treatment group at each assessment. Where changes from baseline were not reported, the mean, standard deviation and the number of patients for each treatment group at each time point were extracted. The baseline assessment is defined as the latest available assessment prior to randomization, but no longer than two months before. </P>
<P>For each outcome measure, data were sought on every patient assessed. To allow an intention-to-treat analysis, the data were sought irrespective of compliance, whether or not the patient was subsequently deemed ineligible, or otherwise excluded from treatment or follow-up. If intention-to-treat data were not available in the publications, ''on-treatment'' or the data of those who completed the trial were extracted and indicated as such. </P>
<P>DATA ANALYSIS<BR/>The outcomes measured in clinical trials of dementia and cognitive impairment often arise from ordinal rating scales. Where the rating scales used in the trials have a reasonably large number of categories (more than 10) the data were treated as continuous arising from a normal distribution.</P>
<P>Summary statistics (n, mean and standard deviation) were required for each assessment time for each treatment group in each trial for change from baseline.</P>
<P>The meta-analysis requires the combination of data from the trials that may not use the same rating scale to assess an outcome. The measure of the treatment difference for any outcome is the weighted mean difference, which is the weighted average of the individual trial estimates, where the pooled trials use the same rating scale or test, or the standardised mean difference, which is the absolute mean difference, where they used different rating scales or tests.</P>
<P>The duration of trials may vary considerably. If the range is considered too great to combine all trials into one meta-analysis it is divided into smaller time periods and a separate meta-analysis conducted for each period. </P>
<P>Overall estimates of the treatment difference have been presented. In all cases the overall estimate from a fixed effects model are presented and a test for heterogeneity using a standard chi-square statistic performed. If there is significant heterogeneity a random effects model is presented.</P>
<P>If a test of heterogeneity is negative then a weighted estimate of the typical treatment effect across trials, is calculated. If, however, there is evidence of heterogeneity of the treatment effect between trials then either only homogeneous results are pooled, or a random-effects model used (in which case the confidence intervals are broader than those of a fixed-effects model).</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>Two studies, <LINK REF="STD-Seal-2002" TYPE="STUDY">Seal 2002</LINK> and <LINK REF="STD-De-La-Fourniere-1997" TYPE="STUDY">De La Fourniere 1997</LINK>, fulfilled randomization criteria for category A or B as defined above. Both enrolled older people with dementia and low blood levels of vitamin B12. The treatment period varied from one month to five months, and the trials also differed in dose, the method of intervention and the definition of low serum vitamin B12 deficiency. As cognitive function outcome scales, the trials used the Mini Mental State Examination (MMSE) (<LINK REF="REF-Folstein-1975" TYPE="REFERENCE">Folstein 1975</LINK>) and the cognitive part of the Alzheimer's Disease Assessment Scale (ADAS-Cog). The Mini-Mental State Examination tests orientation, memory, language and other cognitive functions, the score ranging from 0, severely demented, to 30, normal function. The ADAS-Cog comprises eleven subtests assessing spoken language, comprehension of spoken language, naming objects, following orders, orientation, word recall, ward recognition, recall of instruction test, drawing construction and ideational praxis (<LINK REF="REF-Rosen-1984" TYPE="REFERENCE">Rosen 1984</LINK>). The score range of the ADAS-Cog is from 0-70 with higher scores indicating greater impairment. </P>
<P>The primary aim of <LINK REF="STD-Seal-2002" TYPE="STUDY">Seal 2002</LINK> was to determine the minimum oral daily dose of vitamin B12 required to maintain the serum level of vitamin B12 within a normal range in older people. A three-group design was comprised of placebo and two treatment groups receiving either 10 microgram or 50 microgram of oral cyanocobalamin daily for one month. Thirty-one inpatients were recruited from two centres in Australia with low serum vitamin B12 levels defined as between 100 and 150 pmol/L. Additional inclusion criteria were that patients should not be taking any treatment containing vitamin B12 and there should be no history of malabsorption disorders, pernicious anaemia or neurological disorder other than stroke. Participants were moderately to severely demented as defined by the MMSE. The majority were resident in the community. Their daily intakes of vitamin B12 were estimated and assessments of serum vitamin B12, folate, and homocysteine levels and MMSE measurements were conducted at baseline and one month after enrolment. The primary outcome was the vitamin B12 serum level after treatment to any of three endpoints, normalized serum vitamin B12 levels, normalized homocysteine levels, and the change in MMSE score. The biochemical results were calculated as percentage changes from baseline at endpoint for each group of patients while the performance on the MMSE was calculated as an absolute change. </P>
<P>In the <LINK REF="STD-De-La-Fourniere-1997" TYPE="STUDY">De La Fourniere 1997</LINK> study, eleven community-dwelling inpatients were enrolled from nine centres in France; all participants had a diagnosis of Alzheimer's disease according to DSM III of moderate severity (MMSE scores 11-23). The other criteria for inclusion were low serum vitamin B12 levels, defined for this trial as below 240 pg/ml, and normal serum folate levels. Five patients were randomly assigned to the treatment group and received injections of vitamin B12 1000 microgram daily for 5 days and then one injection each month for 5 months; the remaining six patients received placebo injections. The ADAS-Cog was used to assess cognitive function. </P>
<P>2006 update:</P>
<P>One randomized placebo controlled-trial was found in the new search (<LINK REF="STD-Hvas-2004" TYPE="STUDY">Hvas 2004</LINK>). This study tested the effect of vitamin B12 treatment on cognitive function and symptoms of depression in patients with vitamin B12 deficiency who had not been previously treated with this vitamin. One hundred and forty participants were involved in this trial with early stages of vitamin B12 deficiency defined as increase in plasma methylmalonic acid (0.40-2.00 mcmol/l). Each participant was randomized to receive an injection of 1 mg of vitamin B12 (cyanocobalamin) or placebo weekly for 4 weeks. Patients were assessed at baseline and 3 months later, 2 months after treatment was completed. Three batteries were included to assess the cognitive function: the Cambridge Cognitive Examination (CAMCOG) (<LINK REF="REF-Roth-1986" TYPE="REFERENCE">Roth 1986</LINK>), the Mini-Mental State Examination (MMSE) (<LINK REF="REF-Folstein-1975" TYPE="REFERENCE">Folstein 1975</LINK>) and the 12-words learning test (<LINK REF="REF-Nielsen-1995" TYPE="REFERENCE">Nielsen 1995</LINK>). The major Depression Inventory (MDI) (<LINK REF="REF-Bech-2001" TYPE="REFERENCE">Bech 2001</LINK>) was used to assess depression severity. The CAMCOG is a scale assessing a broad range of cognitive function (orientation, language, memory, concentration, practice, calculation, abstract thinking, perception) and consists of 60 items with a maximum score of 107. The MMSE evaluates cognition in five areas: orientation, immediate recall, attention and calculation, delayed recall, and language. The score may vary between 30 (normal) and 0 (severe impairment). The 12-words learning test is a sensitive test to examine short-term memory, immediate recall and delayed recall after 15 minutes.</P>
<P>At baseline 78 patients had a total score below 90 on CAMCOG, and 40 participants had a MMSE score below 25. The mean MMSE was 26.5 points.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>In the included studies the patients were assigned randomly, and both participants and researchers were blinded to the supplementation. There must be some doubt about the effectiveness of blinding in <LINK REF="STD-De-La-Fourniere-1997" TYPE="STUDY">De La Fourniere 1997</LINK> owing to difficulty in manufacturing pink placebo injections to match those of vitamin B12. Six participants were reported to have dropped out from both <LINK REF="STD-Seal-2002" TYPE="STUDY">Seal 2002</LINK>, and <LINK REF="STD-Hvas-2004" TYPE="STUDY">Hvas 2004</LINK>.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>Meta-analysis revealed no benefit from vitamin B12 supplementation on cognitive function of people with low serum vitamin B12 levels..</P>
<P>In <LINK REF="STD-Seal-2002" TYPE="STUDY">Seal 2002</LINK> performance in the MMSE did not differ between the 50 mcg treatment and the placebo groups (MD -0.60 95% CI -3.06 to 1.86, p=0.63) or between the 10 mcg treatment and placebo groups (MD -1.60 5% CI -3.99 to 0.79, p=0.19). In <LINK REF="STD-De-La-Fourniere-1997" TYPE="STUDY">De La Fourniere 1997</LINK> placebo and treatment groups did not differ significantly in changes in ADAS-Cog scores (MD 0.04 95% CI -5.95 to 6.03, p=0.99). </P>
<P>No adverse effects were reported in either trial. <LINK REF="STD-Seal-2002" TYPE="STUDY">Seal 2002</LINK> noted that 6 of the 31 participants did not complete the study: one patient in the placebo group was excluded because he showed a 75% increase in his serum vitamin B12 level, and 5 were excluded because it was assumed that they would not benefit from small oral doses of vitamin B12. In <LINK REF="STD-De-La-Fourniere-1997" TYPE="STUDY">De La Fourniere 1997</LINK> all patients completed the protocol. </P>
<P>The results from <LINK REF="STD-Hvas-2004" TYPE="STUDY">Hvas 2004</LINK> were not combined with other studies as the data were taken at 3 months after randomization (the trial lasted for only 4 weeks). The follow-up results did not show significant difference between treatment and placebo groups in changes from baseline in cognition function as assessed by the CAMCOG, MMSE, 12-words learning test immediate recall scores (MD -0.6 95% CI -2.2 to 0.9; P=0.43); (MD 0.1 95%CI -0.6 to 0.8, P=0.70); and (MD -0.2 95%CI -0.7 to 0.3, P=0.42) respectively. The was benefit in favour of placebo for the 12-words delayed recall ( MD -0.50, 95% CI -1.0 to 0.0, p=0.05). No significant difference was found in the Major Depression Inventory test between the groups (MD -1.5 95% -3.8 to 0.7; P=0.18). No adverse effects were described in this trial. Six participants did not complete the study: five in the treatment group and one in the placebo. The reasons for dropping out were not specified.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>In <LINK REF="STD-Seal-2002" TYPE="STUDY">Seal 2002</LINK> a daily oral dose of 50 mcg of vitamin B12 significantly increased the average serum levels of older people with initially low values. Selection for the study had, however, excluded anyone with a history of intestinal malabsorption or intrinsic factor deficiency (pernicious anaemia). This finding cannot therefore be extrapolated to the general population. </P>
<P>There was no evidence from the studies that vitamin B12 supplementation had any effect on cognitive function in the short term. <LINK REF="STD-Seal-2002" TYPE="STUDY">Seal 2002</LINK> only lasted for a month and <BR/>
<LINK REF="STD-De-La-Fourniere-1997" TYPE="STUDY">De La Fourniere 1997</LINK> stopped after 5 months because no difference in ADAS-Cog scores was emerging between the placebo and the treatment groups. Much bigger numbers would be needed to detect anything but a very large effect.</P>
<P>The follow-up data after 3 months of Hvas 2004, showed no significant difference between the treatment and placebo group for measurement of cognitive function, with one significant difference in the 12-words learning test after 15 minutes in favour of the placebo group. </P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>There is insufficient evidence of any effect of vitamin B12 therapy on cognitive function of older people with low serum vitamin B12 levels and dementia. </P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Large randomized trials are required to evaluate the value of vitamin B12 for improving cognitive function and preventing or retarding cognitive decline in normal and demented older people. Trials need to use established and validated diagnostic criteria and measures of cognitive function and to be long enough to detect trends. <BR/>
</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>We gratefully acknowledge the contrbutions of the consumer editor, Angela Clayton Turner.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Reem Malouf: selecting trials for inclusion/exclusion, extracting and interpreting data for review, drafting and updating review versions. Moreover, she is responsible for all correspondence related to this review. <BR/>Almudena Areosa Sastre: selection of trials to be included for review, extracting and interpreting data, and assisting in drafting the review.</P>
<P>Original search and update searches: Dymphna Hermans<BR/>Contact editor: Jacqueline Birks<BR/>Consumer editor: Angela Clayton-Turner<BR/>This review has been peer reviewed anonymously</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES>
<P>August 2003: The comments of the consumer editor have been dealt with: additional table 2 (Glossary) has been added as well an additional graph (Homocysteine cycle).</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-11-07 11:58:06 +0000" MODIFIED_BY="Helen Collins">
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-De-La-Fourniere-1997" NAME="De La Fourniere 1997" YEAR="">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>De La Fourniere F, Ferry M, Cnockaert X, Chahwakilian A, Hugonot-Diener L, Baumann F, Nedelec C, Buronfosse D, Meignan S, Fauchier C, Attar C, Belmin J, Piette F</AU>
<TI>Vitamin B12 deficiency and dementia a multicenter epidemiologic and therapeutic study preliminary therapeutic trial</TI>
<TO>Deficience en vitamine B12 et etat dementiel etude epidemiologique multicentrique et therapeutique essai preliminaire</TO>
<SO>Semaine Des Hopitaux</SO>
<YR>1997</YR>
<VL>73</VL>
<NO>5-6</NO>
<PG>133-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hvas-2004" NAME="Hvas 2004" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hvas AM, Juul S, Lauritzen L, Nexo E, Ellegaard J</AU>
<TI>No effect of vitamin B12 treatment on cognitive function and depression: a randomized placebo controlled study</TI>
<SO>Journal of Affective Disorders</SO>
<YR>2004</YR>
<VL>81</VL>
<PG>269-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Seal-2002" NAME="Seal 2002" YEAR="">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Seal EC, Metz J, Flicker L, Melny J</AU>
<TI>A randomized double blind placebo controlled study of oral vitamin B12 supplementation in older patients with subnormal or borderline serum vitamin B12 concentrations</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>2002</YR>
<VL>50</VL>
<NO>1</NO>
<PG>146-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Abyad-2002" NAME="Abyad 2002" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abyad A</AU>
<TI>Prevalence of vitamin B12 deficiency among demented patients and cognitive recovery with cobalamin replacement</TI>
<SO>Journal of nutrition, health and aging</SO>
<YR>2002</YR>
<VL>6</VL>
<NO>4</NO>
<PG>245-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eastley-2000" NAME="Eastley 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eastley R, Wilcock G, Bucks R</AU>
<TI>Vitamin B12 deficiency in demented and cognitive impairment the effects of treatment on neuropsychological function</TI>
<SO>International journal of geriatric psychiatry</SO>
<YR>2000</YR>
<VL>15</VL>
<PG>226-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hughes-1970" NAME="Hughes 1970" YEAR="1970">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hughes D, Elwood PC, Shinton NK, Wrighton RJ</AU>
<TI>Clinical trial of the effect of vitamin B12 in elderly subjects with low serum B12 levels</TI>
<SO>British Medical Journal</SO>
<YR>1970</YR>
<VL>unknown</VL>
<PG>458-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kwok-1998" NAME="Kwok 1998" YEAR="">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kwok T, Tang C, Woo J, Lai WK, Law LK, Pang CP</AU>
<TI>Randomized trial of the effect of supplementation on the cognitive function of older people with subnormal cobalamin levels</TI>
<SO>International Journal of Geriatric Psychiatry</SO>
<YR>1998</YR>
<VL>13</VL>
<NO>9</NO>
<PG>611-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martin-1992" NAME="Martin 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martin DC, Francis J, Protech J, Jacob H</AU>
<TI>Time dependency of cognitive recovery with cobalamin replacement report of a pilot study</TI>
<SO>Journal of the American Geriatric Society</SO>
<YR>1992</YR>
<VL>40</VL>
<PG>168-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nagga-2002" NAME="Nagga 2002" YEAR="">
<REFERENCE PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Nagga K, Lindehammar H, Marcusson J</AU>
<TO>Effects of cobalamin supplementation a study on dementia patients with cobalamin deficiency</TO>
<SO>The 8th international conference on Alzheimer's disease and related disorders, Stockholm, Sweden</SO>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Takao-2001" NAME="Takao 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Takao I, Yamadera-Hiroshi I, Ritsuko I, Suzuki H</AU>
<TI>Effects of vitamin B12 on bright light on cognitive and sleep wake rhythm in Alzheimer type dementia</TI>
<SO>Psychiatry and Clinical Neurosciences</SO>
<YR>2001</YR>
<VL>55</VL>
<PG>281-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Teunisse-1996" NAME="Teunisse 1996" YEAR="">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Teunisse S, Bollen AE, Van Gool WA, Walstra GJM</AU>
<TI>Dementia and subnormal levels of vitamin B12 effects of replacement therapy on dementia</TI>
<SO>Journal of Neurology</SO>
<YR>1996</YR>
<VL>243</VL>
<PG>522-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-11-07 11:58:06 +0000" MODIFIED_BY="Helen Collins">
<ADDITIONAL_REFERENCES MODIFIED="2008-11-07 11:57:21 +0000" MODIFIED_BY="Helen Collins">
<REFERENCE ID="REF-Baik-1999" NAME="Baik 1999" TYPE="JOURNAL_ARTICLE">
<AU>Baik HW, Russell RM</AU>
<TI>Vitamin B12 deficiency in the elderly</TI>
<SO>Annual Review of Nutrition</SO>
<YR>1999</YR>
<VL>19</VL>
<PG>357-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bech-2001" NAME="Bech 2001" TYPE="JOURNAL_ARTICLE">
<AU>Bech P, Rasmussen NA, Olsen LR, Noerholm V, Abildgaard W</AU>
<TI>The sensitivity and specificity of the major depression inventory using the present state examination as the index diagnostic validity</TI>
<SO>J. Affect. Disord</SO>
<YR>2001</YR>
<VL>66</VL>
<PG>159-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Byrne-1987" NAME="Byrne 1987" TYPE="JOURNAL_ARTICLE">
<AU>Byrne EJ</AU>
<TI>Reversible dementia</TI>
<SO>International Journal of Geriatric Psychiatry</SO>
<YR>1987</YR>
<VL>2</VL>
<PG>73-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carmel-1995" NAME="Carmel 1995" TYPE="OTHER">
<AU>Carmel R, Gott PS, Waters CH, Cairo K, Green R, Bondareff W, DeGiorgio CM, Cummings JL, Jacobsen DW, Buckwalter G, et al.</AU>
<TI>The frequently low cobalamin levels in dementia usually signify treatable metabolic, neurologic and electrophysiologic abnormalities.</TI>
<SO>European journal of haematology</SO>
<YR>1995</YR>
<VL>54</VL>
<NO>4</NO>
<PG>245-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chalmers-1983" NAME="Chalmers 1983" TYPE="JOURNAL_ARTICLE">
<AU>Chalmers TC, Celano P, Sacks HS, Smith H</AU>
<TI>Bias in treatment assignment in controlled clinical trials</TI>
<SO>New England Journal of Medicine</SO>
<YR>1983</YR>
<VL>309</VL>
<PG>1358-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clarfield-1988" NAME="Clarfield 1988" TYPE="JOURNAL_ARTICLE">
<AU>Clarfield AM</AU>
<TI>The reversible dementia do they reverse</TI>
<SO>Annales of Internal Medicine</SO>
<YR>1988</YR>
<VL>109</VL>
<PG>476-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clarke-1991" NAME="Clarke 1991" TYPE="JOURNAL_ARTICLE">
<AU>Clarke R, Day L, Robinson K, Naughten E, Cahalance S, Fowler B, Graham I</AU>
<TI>Hyperhomocysteinemia an independent risk factor for vascular disease</TI>
<SO>New England Journal of Medicine</SO>
<YR>1991</YR>
<VL>324</VL>
<PG>1149-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clarke-1998" NAME="Clarke 1998" TYPE="OTHER">
<AU>Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, Ueland PM</AU>
<TI>Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease.</TI>
<SO>Archives of neurology</SO>
<YR>1998</YR>
<VL>55</VL>
<NO>11</NO>
<PG>1449-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Crowe-1997" NAME="Crowe 1997" TYPE="JOURNAL_ARTICLE">
<AU>Crowe SE, Ross CK</AU>
<TI>Effect of folate deficiency and folate and B12 excess on memory functioning in young chicks</TI>
<SO>Pharmacol. Biochem. Behav</SO>
<YR>1997</YR>
<VL>February</VL>
<PG>189-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Elsborg-1976" NAME="Elsborg 1976" TYPE="JOURNAL_ARTICLE">
<AU>Elsborg L, Lund V, Bastrup-Madsen P</AU>
<TI>Serum B12 levels in the aged</TI>
<SO>Acta Medica Scandinavia</SO>
<YR>1976</YR>
<VL>200</VL>
<PG>209-314</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Elwood-1971" NAME="Elwood 1971" TYPE="JOURNAL_ARTICLE">
<AU>Elwood PC, Shinton NK, Wilson CID</AU>
<TI>Haemoglobin vitamin B12 and folate levels in the elderly</TI>
<SO>British Journal of haematology</SO>
<YR>1971</YR>
<VL>21</VL>
<PG>557-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Erkinjuntti-1986" NAME="Erkinjuntti 1986" TYPE="JOURNAL_ARTICLE">
<AU>Erkinjuntti T, Wikstrom J, Palo J</AU>
<TI>Dementia among medical inpatients evaluation of 2000 admissions</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1986</YR>
<VL>146</VL>
<PG>1923-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Firkin-1989" NAME="Firkin 1989" TYPE="BOOK">
<AU>Firkin F</AU>
<SO>De Gruchy's Clinical haematology in medical practice</SO>
<YR>1989</YR>
<EN>5th</EN>
<PB>Blackwell</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Folstein-1975" NAME="Folstein 1975" TYPE="JOURNAL_ARTICLE">
<AU>Folstein MF, Folstein SE, McHugh PR</AU>
<TI>Mini mental state a practical method for grading the cognitive state of patients for the clinician</TI>
<SO>Journal of Psychiatric Research</SO>
<YR>1975</YR>
<VL>12</VL>
<PG>189-98</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gaffney-1957" NAME="Gaffney 1957" TYPE="JOURNAL_ARTICLE">
<AU>Gaffney GW, Horonick A, Okuda K et al</AU>
<TI>Vitamin B12 concentrations in 528 apparently healthy human subjects of ages 12-24</TI>
<SO>Journal of Gerantology</SO>
<YR>1957</YR>
<VL>12</VL>
<PG>32-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goodwin-1983" NAME="Goodwin 1983" TYPE="JOURNAL_ARTICLE">
<AU>Goodwin JS, Goodwin Jm, Garry PJ</AU>
<TI>Association between nutritional status and cognitive functioning in a healthy elderly population</TI>
<SO>Journal of the American Medical Association</SO>
<YR>1983</YR>
<VL>249</VL>
<PG>2917-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Healton-1991" NAME="Healton 1991" TYPE="JOURNAL_ARTICLE">
<AU>Healton EB, Savage DG, Brust JCM</AU>
<TI>Neurologic aspects of cobalamin deficiency</TI>
<SO>Medicine</SO>
<YR>1991</YR>
<VL>70</VL>
<PG>229-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hector-1988" NAME="Hector 1988" TYPE="JOURNAL_ARTICLE">
<AU>Hector M, Burton JR</AU>
<TI>What are the psychiatric manifestations of vitamin B12 deficiency</TI>
<SO>Journal of the American Geriatric Society</SO>
<YR>1988</YR>
<VL>36</VL>
<PG>1105-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Herbert-1996" NAME="Herbert 1996" TYPE="BOOK">
<AU>Herbert V</AU>
<SO>Life science: In present knowledge in nutrition</SO>
<YR>1996</YR>
<PB>Inst Press</PB>
<CY>Washington</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ikeda-1992" NAME="Ikeda 1992" TYPE="JOURNAL_ARTICLE">
<AU>Ikeda T// Yamamoto K// Takahashi K// kaku Y// Uchiyama M //Yamada M Treatment of Alzheimer-type dementia with intravenous mecobalamin. Clinical therapeutics 1992, 14, 3: 426-73</AU>
<TI>Treatment of Alzheimer type dementia with intravenous mecobalamin</TI>
<SO>Clinical Therapeutica</SO>
<YR>1992</YR>
<VL>14</VL>
<NO>3</NO>
<PG>426-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Joosten-1997" NAME="Joosten 1997" TYPE="JOURNAL_ARTICLE">
<AU>Joosten E, Lesaffre E, Ghekiere V, Deremaeker L, Pelemans W, Dejaeger E</AU>
<TI>Is metaolic evidence for vitamin b12 and folate deficiency more freguent in elderly patients with alzheimer's disease</TI>
<SO>Journal of Gerontology A bio sci Med Sci</SO>
<YR>1997</YR>
<VL>52</VL>
<PG>M76-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jorm-1990" NAME="Jorm 1990" TYPE="BOOK">
<AU>Jorm AF</AU>
<SO>The epidemiology of Alzheimer's disease and related disorders</SO>
<YR>1990</YR>
<PB>Champan and Hall</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kilpatrick-1965" NAME="Kilpatrick 1965" TYPE="JOURNAL_ARTICLE">
<AU>Kilpatrick GS, Withey JL</AU>
<TI>The serum B12 concentration in the general population</TI>
<SO>Scand J Heamatol</SO>
<YR>1965</YR>
<VL>2</VL>
<PG>220-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kwan-2002" NAME="Kwan 2002" TYPE="OTHER">
<AU>Kwan LL, Bermudez OI, Tucker KL</AU>
<TI>Low vitamin B-12 intake and status are more prevalent in Hispanic older adults of Caribbean origin than in neighborhood-matched non-Hispanic whites.</TI>
<SO>Journal of nutrition, The</SO>
<YR>2002</YR>
<VL>132</VL>
<NO>7</NO>
<PG>2059-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-La-Rue-1997" NAME="La Rue 1997" TYPE="OTHER">
<AU>La Rue A, Koehler KM, Wayne SJ, Chiulli SJ, Haaland KY, Garry PJ</AU>
<TI>Nutritional status and cognitive functioning in a normally aging sample: a 6-y reassessment</TI>
<SO>American journal of clinical nutrition, The</SO>
<YR>1997</YR>
<VL>65</VL>
<NO>1</NO>
<PG>20-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Larson-1985" NAME="Larson 1985" TYPE="JOURNAL_ARTICLE">
<AU>Lrson EB, Reifler BV, Sumi SM</AU>
<TI>Diagnostic evaluation of 200 eldely outpatients with suspected dementia</TI>
<SO>Journal of Gerontology</SO>
<YR>1985</YR>
<VL>40</VL>
<PG>356-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Levitt-1992" NAME="Levitt 1992" TYPE="JOURNAL_ARTICLE">
<AU>Levitt AJ, Karlinsky H</AU>
<TI>Folate vitamin B12 and cognitive impairment in patients with alzheimer's disease</TI>
<SO>Acta Psychiatrica Scandanavica</SO>
<YR>1992</YR>
<VL>86</VL>
<PG>301-05</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lindenbaum-1994" NAME="Lindenbaum 1994" TYPE="JOURNAL_ARTICLE">
<AU>Lindenbaum J, Rosenberg I, Wilson PWF, Stabler S, Allen RH</AU>
<TI>Prevalence of cobalamin deficiency in the Framingham elderly population</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1994</YR>
<VL>60</VL>
<PG>2-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Malouf-2003a" MODIFIED="2008-11-07 11:57:21 +0000" MODIFIED_BY="Helen Collins" NAME="Malouf 2003a" NOTES="&lt;p&gt;Malouf R, Grimley Evans J, Areosa Sastre A. Folic acid with or without vitamin B12 for cognition and dementia. The Cochrane Database of Systematic Reviews 2003, Issue 4. Art. No.: CD004514. DOI: 10.1002/14651858.CD004514&lt;/p&gt;" NOTES_MODIFIED="2008-11-07 11:57:21 +0000" NOTES_MODIFIED_BY="Helen Collins" TYPE="COCHRANE_REVIEW">
<AU>Malouf R, Grimley Evans J, Areosa Sastre A</AU>
<TI>Folic acid with or without vitamin B12 for cognition and dementia</TI>
<SO>The Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>4. Art. No.: CD004514. DOI: 10.1002/14651858.CD004514</NO>
<PB>John Wiley &amp; Sons Ltd</PB>
<CY>Chichester</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marcell-1985" NAME="Marcell 1985" TYPE="OTHER">
<AU>Marcell PD, Stabler SP, Podell ER, Allen RH</AU>
<TI>Quantitation of methylmalonic acid and other dicarboxylic acids in normal serum and urine using capillary gas chromatography-mass spectrometry</TI>
<SO>Analytical biochemistry</SO>
<YR>1985</YR>
<VL>150</VL>
<NO>1</NO>
<PG>58-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marcus-1987" NAME="Marcus 1987" TYPE="OTHER">
<AU>Marcus DL, Shadick N, Crantz J, Gray M, Hernandez F, Freedman ML</AU>
<TI>Low serum B12 levels in a hematologically normal elderly subpopulation</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>1987</YR>
<VL>35</VL>
<NO>7</NO>
<PG>635-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marsden-1972" NAME="Marsden 1972" TYPE="JOURNAL_ARTICLE">
<AU>Marsden CD, Harrison MJG</AU>
<TI>Presenile dementia</TI>
<SO>British Medical Journal</SO>
<YR>1972</YR>
<VL>2</VL>
<PG>249-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Matcher-1994" NAME="Matcher 1994" TYPE="JOURNAL_ARTICLE">
<AU>Matcher DB, McCrory DC, Millington DS, Feusser JR</AU>
<TI>Performance of serum cobalamin assay for diagnosis of cobalamin deficiency</TI>
<SO>Am J Med Science</SO>
<YR>1994</YR>
<VL>304</VL>
<PG>276-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McCaddon-2001" NAME="McCaddon 2001" TYPE="JOURNAL_ARTICLE">
<AU>McCaddon A, Husdon P, Davis G, Hughes A, Williams JHH, Wilkinson C</AU>
<TI>Homocysteine and cognitive decline in healthy elderly</TI>
<SO>Dementia and Geriatric Cognitive Disorders</SO>
<YR>2001</YR>
<VL>12</VL>
<PG>309-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Meins-2000" NAME="Meins 2000" TYPE="JOURNAL_ARTICLE">
<AU>Meins W, Muller-Thomnen T, Meier-Baumgartner HP</AU>
<TI>Subnormal serum vitamin B12 and behavioural and psychological sympyoms in Alzheimer's disease</TI>
<SO>International Journal of Geriatric Psychiatry</SO>
<YR>2000</YR>
<VL>15</VL>
<NO>5</NO>
<PG>415-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Metz-1996" NAME="Metz 1996" TYPE="JOURNAL_ARTICLE">
<AU>Metz J, Bell A, Flicker L, Bottiglieri T, Ibrahim J, Seal E, Schultz D, Savioa D, Mcgrath KM</AU>
<TI>The significance of subnormal serum vitamin B12 concentration in the elderly a case study</TI>
<SO>Journal of American Geriatric Society</SO>
<YR>1996</YR>
<VL>44</VL>
<PG>1355-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mulrow-1997" NAME="Mulrow 1997" TYPE="BOOK">
<AU>Mulrow CD, Oxman AD</AU>
<SO>Cochrane Collaboration Handbook</SO>
<YR>1997</YR>
<EN>The Cochrane Collaboration, issue 1, updated quarterly</EN>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nielsen-1995" NAME="Nielsen 1995" TYPE="JOURNAL_ARTICLE">
<AU>Nielsen H, Lolk A, Krag-Sorensen P</AU>
<TI>Normative data for eight neuropsychological tests gathered from a random sample of Danes aged 64-83 years</TI>
<SO>Nordisk Psykologi</SO>
<YR>1995</YR>
<VL>47</VL>
<PG>241-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pennypacker-1992" NAME="Pennypacker 1992" TYPE="JOURNAL_ARTICLE">
<AU>Pennypacker LC, Allen RH, Kelly JP, Matthews LM, Grigsby J, Kaye K, Lindenbaum J, Sally S</AU>
<TI>High prevalence of cobalamin deficiency in elderly outpatients</TI>
<SO>Journal of the American geriatric society</SO>
<YR>1992</YR>
<VL>40</VL>
<PG>1197-04</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Regland-1999" NAME="Regland 1999" TYPE="JOURNAL_ARTICLE">
<AU>Regland B, Blennow K, Germgard T, Hoch Scmidt AC, Gottfries CG</AU>
<TI>The role of the polymorphic genes apolipoprotein E and methyle-tetrahydrofolate reductase in the development of dementia Alzheimer type</TI>
<SO>Dementia Geriatr Cog Disord</SO>
<YR>1999</YR>
<VL>10</VL>
<PG>245-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Riggs-1996" NAME="Riggs 1996" TYPE="JOURNAL_ARTICLE">
<AU>Riggs KM, Spire A, Tucker K, Rush D</AU>
<TI>Relations of vitamin B12 vitamin B6 folate and homocysteine to cognitive function in the normative aging study</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1996</YR>
<VL>63</VL>
<PG>306-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rosen-1984" NAME="Rosen 1984" TYPE="JOURNAL_ARTICLE">
<AU>Rosen WG, Mohs RC, Davis KL</AU>
<TI>A new rating scale for Alzheimer's disease</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1984</YR>
<VL>141</VL>
<PG>1356-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Roth-1986" NAME="Roth 1986" TYPE="JOURNAL_ARTICLE">
<AU>Roth M, Tym E, Mountjoy CQ, Huppert FA, Hendrie H et al</AU>
<TI>CAMDEX. A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the elderly with special reference to the early detection of dementia</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1986</YR>
<VL>149</VL>
<PG>698-09</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman D</AU>
<TI>Empirical evidence of bais</TI>
<SO>Journal of American Medical Association</SO>
<YR>1995</YR>
<VL>273</VL>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shahar-2001" NAME="Shahar 2001" TYPE="JOURNAL_ARTICLE">
<AU>Shahar A, Feigen L, Shara DR, Levy S, Seligsohn U</AU>
<TI>High prevalence and impact of subnormal serum vitamin B12 levels in Israeil elders admits to a geriatric hospital</TI>
<SO>Journal of Nutrition Health and Aging</SO>
<YR>2001</YR>
<VL>52</VL>
<PG>124-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shulman-1967" NAME="Shulman 1967" TYPE="JOURNAL_ARTICLE">
<AU>Shulman R</AU>
<TI>Psychiatric aspects of pernicious anaemia a prospective controlled investigation</TI>
<SO>British Medical Journal</SO>
<YR>1967</YR>
<VL>3</VL>
<PG>266-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stabler-1986" NAME="Stabler 1986" TYPE="OTHER">
<AU>Stabler SP, Marcell PD, Podell ER, Allen RH, Lindenbaum J</AU>
<TI>Assay of methylmalonic acid in the serum of patients with cobalamin deficiency using capillary gas chromatography-mass spectrometry</TI>
<SO>Journal of clinical investigation, The</SO>
<YR>1986</YR>
<VL>77</VL>
<NO>5</NO>
<PG>1606-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stabler-1990" NAME="Stabler 1990" TYPE="JOURNAL_ARTICLE">
<AU>Stabler SP, Aleen Rh, Savage DG, Lindenbaum J</AU>
<TI>Clinical spectrum and diagnosis of cobalamin deficiency</TI>
<SO>Blood</SO>
<YR>1990</YR>
<VL>79</VL>
<PG>871-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stabler-1997" NAME="Stabler 1997" TYPE="JOURNAL_ARTICLE">
<AU>Stabler SP, Lindenbaum J, Allen RH</AU>
<TI>Vitamin B12 deficiency in the elderly current dilemmas</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1997</YR>
<VL>66</VL>
<PG>741-59</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tripathi-2001" NAME="Tripathi 2001" TYPE="JOURNAL_ARTICLE">
<AU>Tripathi M, Sheshadri S, Padma MV, Jain S, Meheshwari MC, Behari M</AU>
<TI>Serum cobalamin levels in dementias</TI>
<SO>Neurology India</SO>
<YR>2001</YR>
<VL>49</VL>
<PG>284-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Van-Asselt--1998" NAME="Van Asselt  1998" TYPE="JOURNAL_ARTICLE">
<AU>Van Asselt DZB, De Groot Lcpgm, Van Staveren WA et al</AU>
<TI>Role of cobalamin intake and atrophic gastritis in mild cobalamin deficiency in older Dutch subjects</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1998</YR>
<VL>68</VL>
<PG>328-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-van-Asselt-2001" NAME="van Asselt 2001" TYPE="OTHER">
<AU>van Asselt DZ, Pasman JW, van Lier HJ, Vingerhoets DM, Poels PJ, Kuin Y, Blom HJ, Hoefnagels WH</AU>
<TI>Cobalamin supplementation improves cognitive and cerebral function in older, cobalamin-deficient persons.</TI>
<SO>Journals of gerontology, The. Series A, Biological sciences and medical sciences</SO>
<YR>2001</YR>
<VL>56</VL>
<NO>12</NO>
<PG>M775-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Walstra-1997" NAME="Walstra 1997" TYPE="JOURNAL_ARTICLE">
<AU>Walstra GJM, Tunisse S, Van Gool WA, Van Creuel H</AU>
<TI>Reversible dementia in elderly patients referred to a memory clinic</TI>
<SO>Journal of Neurology</SO>
<YR>1997</YR>
<VL>244</VL>
<NO>1</NO>
<PG>71-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wivel-1988" NAME="Wivel 1988" TYPE="JOURNAL_ARTICLE">
<AU>Wivel ME</AU>
<TI>NIMH report. NIH consensus conference stresses need to identify reversible causes of dementia</TI>
<SO>Hosp-Community-Psychiatry</SO>
<YR>1988</YR>
<VL>39</VL>
<NO>1</NO>
<PG>22-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3276593"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2008-11-07 11:58:06 +0000" MODIFIED_BY="Helen Collins">
<REFERENCE ID="REF-Malouf-2003b" MODIFIED="2008-11-07 11:58:06 +0000" MODIFIED_BY="Helen Collins" NAME="Malouf 2003b" TYPE="COCHRANE_REVIEW">
<AU>Malouf R, Areosa Sastre A</AU>
<TI>Vitamin B12 for cognition</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2008-11-07 11:58:06 +0000" MODIFIED_BY="Helen Collins">
<IDENTIFIER MODIFIED="2008-11-07 11:58:06 +0000" MODIFIED_BY="Helen Collins" TYPE="DOI" VALUE="10.1002/14651858.CD004394"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-De-La-Fourniere-1997">
<CHAR_METHODS>
<P>Randomized double-blind placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: France<BR/>Number: 11 randomized <BR/>No drop outs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Placebo<BR/>2. 5 injections of 1000 microgram of vitamin B12 per day for 5 days then one injection per month for 5 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>ADAS<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Hvas-2004">
<CHAR_METHODS>
<P>Randomized double-blind placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Denmark<BR/>Number: 140 randomized<BR/>Mean age in the treatment: 75 years<BR/>Mean age in the placebo group: 74 years<BR/>5 patients dropped out in the treatment group<BR/>1 patient dropped out in the placebo group</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1.Placebo<BR/>2. 1 mg of cyanocobalamin weekly for 4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1.CAMCOG<BR/>2. MMSE<BR/>3.12-words learning test<BR/>4. MDI<BR/>5. P-MMA</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Seal-2002">
<CHAR_METHODS>
<P>Randomized double-blind placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Australia<BR/>Number: 31 randomized<BR/>Age: mean 81.4 years<BR/>Inclusion Criteria: serum B12 level &lt; 150 pmol/L , the majority living at home<BR/>Exclusion criteria: Pernicious anaemia, history of malabsorption, vitamin B12 treatment or supplementation<BR/>6: dropped-out</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Placebo<BR/>2. Oral cyanocobalamin in two doses: 10 and 50 microgram daily for 1 month<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>MMSE<BR/>Serum vitamin B12/folate/Hcy</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>3 people had diabetes mellitus type II</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>MMSE: Mini Mental State Examination<BR/>ADAS: Alzheimer's Disease Assessment Scale <BR/>CAMCOG: Cambridge Cognitive Examination<BR/>MDI: Major Depression Inventory<BR/>P-MMA: Plasma Methylmalonic Acid</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Abyad-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Single-blind</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Eastley-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>No intervention in the control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hughes-1970">
<CHAR_REASON_FOR_EXCLUSION>
<P>No measure of cognitive function</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kwok-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>No intervention in the control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Martin-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>No control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nagga-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>No control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Takao-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not clear whether randomized</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Teunisse-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>No randomization</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-De-La-Fourniere-1997">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hvas-2004">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Seal-2002">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-11-07 11:55:14 +0000" MODIFIED_BY="Helen Collins">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2008-11-07 11:55:14 +0000" MODIFIED_BY="Helen Collins" NO="1">
<TITLE>Glossary</TITLE>
<TABLE COLS="2" ROWS="6">
<TR>
<TH>
<P>Term</P>
</TH>
<TH>
<P>Defination</P>
</TH>
</TR>
<TR>
<TD>
<P>Haemopothoietic system</P>
</TD>
<TD>
<P>The system that is responsible for production of the blood cells, which includes the bone marrow, liver, spleen, lymph nodes and thymus.</P>
</TD>
</TR>
<TR>
<TD>
<P>Polyneuropathy</P>
</TD>
<TD>
<P>A generalized disturbance in peripheral nerves which could be acute (beginning suddenly) or chronic (developing gradually). The commonest type which involves both sensory and motor nerves</P>
</TD>
</TR>
<TR>
<TD>
<P>Subacute combined degeneration of the spinal cord</P>
</TD>
<TD>
<P>A progressive disorder that is due to vitamin B12 deficiency and produces weakness, tingling and other abnormal sensations</P>
</TD>
</TR>
<TR>
<TD>
<P>Hyperhomocysteine</P>
</TD>
<TD>
<P>A raised level in the plasma concentration of the homocysteine (a sulphur-amino acid)</P>
</TD>
</TR>
<TR>
<TD>
<P>Hypochlorhydria</P>
</TD>
<TD>
<P>A decline in the secretion of the hydrochloric acid (Hcl), that is secreted from the parietal cells in the stomach</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>vitamin B12 supplementation versus placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="6.026612590672845" CI_START="-5.946612590672845" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.040000000000000036" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.01" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.9895514848683074" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="6" TOTAL_2="5" UNITS="" WEIGHT="100.0" Z="0.0130956460258924">
<NAME>ADAS-Cog (change from baseline at 5 months)</NAME>
<GROUP_LABEL_1>Vitamin B12</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vitamin B12</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="6.026612590672845" CI_START="-5.946612590672845" DF="0.0" EFFECT_SIZE="0.040000000000000036" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.01" NO="1" P_CHI2="1.0" P_Z="0.9895514848683074" STUDIES="1" TAU2="0.0" TOTAL_1="6" TOTAL_2="5" WEIGHT="100.0" Z="0.0130956460258924">
<NAME>10 mg dose in 5 months</NAME>
<CONT_DATA CI_END="6.026612590672845" CI_START="-5.946612590672845" EFFECT_SIZE="0.040000000000000036" ESTIMABLE="YES" MEAN_1="1.12" MEAN_2="1.08" ORDER="104582" SD_1="5.9" SD_2="4.2" SE="3.05445030515585" STUDY_ID="STD-De-La-Fourniere-1997" TOTAL_1="6" TOTAL_2="5" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.3266965533513621" CI_END="0.5991701600677344" CI_START="-2.828427651401201" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.1146287456667334" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" NO="2" P_CHI2="0.5676109246026797" P_Q="0.5676109246026797" P_Z="0.20240457766303332" Q="0.3266965533513621" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="19" TOTAL_2="16" UNITS="" WEIGHT="200.0" Z="1.2747307693627012">
<NAME>MMSE (change from baseline at 4 weeks)</NAME>
<GROUP_LABEL_1>Vitamin B12</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours vitamin B12</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.7889817974332436" CI_START="-3.9889817974332438" DF="0.0" EFFECT_SIZE="-1.6" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.01" NO="1" P_CHI2="1.0" P_Z="0.18929450388999672" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="8" WEIGHT="100.0" Z="1.3126690118080384">
<NAME>10 microg/day for four weeks</NAME>
<CONT_DATA CI_END="0.7889817974332436" CI_START="-3.9889817974332438" EFFECT_SIZE="-1.6" ESTIMABLE="YES" MEAN_1="0.0" MEAN_2="1.6" ORDER="104583" SD_1="2.9" SD_2="2.1" SE="1.2188906613984885" STUDY_ID="STD-Seal-2002" TOTAL_1="9" TOTAL_2="8" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.8599304883062087" CI_START="-3.059930488306209" DF="0.0" EFFECT_SIZE="-0.6000000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.02" NO="2" P_CHI2="1.0" P_Z="0.6326121255275579" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="8" WEIGHT="100.0" Z="0.4780535044848993">
<NAME>50 microg/day for four weeks</NAME>
<CONT_DATA CI_END="1.8599304883062087" CI_START="-3.059930488306209" EFFECT_SIZE="-0.6000000000000001" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="1.6" ORDER="104584" SD_1="3.2" SD_2="2.1" SE="1.2550896382330627" STUDY_ID="STD-Seal-2002" TOTAL_1="10" TOTAL_2="8" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.9463017237374565" CI_START="-2.146301723737456" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.5999999999999999" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.03" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.44694961997704685" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="65" TOTAL_2="69" UNITS="" WEIGHT="100.0" Z="0.760510301884459">
<NAME>CAMCOG (change from baseline) in 3 months follow-up from baseline</NAME>
<GROUP_LABEL_1>vitamin B12</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours vitamin B12</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.9463017237374565" CI_START="-2.146301723737456" DF="0.0" EFFECT_SIZE="-0.5999999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.01" NO="1" P_CHI2="1.0" P_Z="0.44694961997704685" STUDIES="1" TAU2="0.0" TOTAL_1="65" TOTAL_2="69" WEIGHT="100.0" Z="0.760510301884459">
<NAME>1mg dose weekly for 4 weeks</NAME>
<CONT_DATA CI_END="0.9463017237374565" CI_START="-2.146301723737456" EFFECT_SIZE="-0.5999999999999999" ESTIMABLE="YES" MEAN_1="1.3" MEAN_2="1.9" ORDER="104585" SD_1="4.8" SD_2="4.3" SE="0.7889439479166388" STUDY_ID="STD-Hvas-2004" TOTAL_1="65" TOTAL_2="69" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.7881362747139896" CI_START="-0.5881362747139897" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.09999999999999998" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.04" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.7757804629071204" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="65" TOTAL_2="69" UNITS="" WEIGHT="100.0" Z="0.28482207036021673">
<NAME>MMSE (change from baseline) in 3 months follow-up from baseline</NAME>
<GROUP_LABEL_1>Vitamin B12</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours vitamin B12</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.7881362747139896" CI_START="-0.5881362747139897" DF="0.0" EFFECT_SIZE="0.09999999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.01" NO="1" P_CHI2="1.0" P_Z="0.7757804629071204" STUDIES="1" TAU2="0.0" TOTAL_1="65" TOTAL_2="69" WEIGHT="100.0" Z="0.28482207036021673">
<NAME>1mg dose weekly for 4 weeks</NAME>
<CONT_DATA CI_END="0.7881362747139895" CI_START="-0.5881362747139895" EFFECT_SIZE="0.09999999999999998" ESTIMABLE="YES" MEAN_1="0.3" MEAN_2="0.2" ORDER="104586" SD_1="2.3" SD_2="1.7" SE="0.3510963875570779" STUDY_ID="STD-Hvas-2004" TOTAL_1="65" TOTAL_2="69" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.291019062593215" CI_START="-0.6910190625932151" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.2" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.05" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.42468191664273636" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="65" TOTAL_2="69" UNITS="" WEIGHT="100.0" Z="0.7983250076642289">
<NAME>12 words learning test, immediate recall, (change from baseline) in 3 months follow-up from baseline</NAME>
<GROUP_LABEL_1>Vitamin B12</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours vitamin B12</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.291019062593215" CI_START="-0.6910190625932151" DF="0.0" EFFECT_SIZE="-0.2" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.01" NO="1" P_CHI2="1.0" P_Z="0.42468191664273636" STUDIES="1" TAU2="0.0" TOTAL_1="65" TOTAL_2="69" WEIGHT="100.0" Z="0.7983250076642289">
<NAME>1mg dose weekly for 4 weeks</NAME>
<CONT_DATA CI_END="0.291019062593215" CI_START="-0.6910190625932151" EFFECT_SIZE="-0.2" ESTIMABLE="YES" MEAN_1="0.2" MEAN_2="0.4" ORDER="104587" SD_1="1.4" SD_2="1.5" SE="0.25052453334158725" STUDY_ID="STD-Hvas-2004" TOTAL_1="65" TOTAL_2="69" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0106601739682321" CI_START="-1.010660173968232" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.49999999999999994" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.06" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.05497810909820776" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="65" TOTAL_2="69" UNITS="" WEIGHT="100.0" Z="1.9190491881416842">
<NAME>12 words learning test, 15 min delayed recall (change from baseline) in 3 months follow-up from baseline</NAME>
<GROUP_LABEL_1>Vitamin B12</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours vitamin B12</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0106601739682321" CI_START="-1.010660173968232" DF="0.0" EFFECT_SIZE="-0.49999999999999994" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.01" NO="1" P_CHI2="1.0" P_Z="0.05497810909820776" STUDIES="1" TAU2="0.0" TOTAL_1="65" TOTAL_2="69" WEIGHT="100.0" Z="1.9190491881416842">
<NAME>1mg dose weekly for 4 weeks</NAME>
<CONT_DATA CI_END="0.0106601739682321" CI_START="-1.010660173968232" EFFECT_SIZE="-0.49999999999999994" ESTIMABLE="YES" MEAN_1="0.2" MEAN_2="0.7" ORDER="104588" SD_1="1.3" SD_2="1.7" SE="0.26054569267407685" STUDY_ID="STD-Hvas-2004" TOTAL_1="65" TOTAL_2="69" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.5521113098363126" CI_START="-3.752111309836313" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.6" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.07" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.14507582791148776" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="65" TOTAL_2="69" UNITS="" WEIGHT="100.0" Z="1.457146924014169">
<NAME>Major Depression Inventory (change from baseline) in 3 months follow-up from baseline</NAME>
<GROUP_LABEL_1>Vitamin B12</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vitamin B12</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5521113098363126" CI_START="-3.752111309836313" DF="0.0" EFFECT_SIZE="-1.6" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.01" NO="1" P_CHI2="1.0" P_Z="0.14507582791148776" STUDIES="1" TAU2="0.0" TOTAL_1="65" TOTAL_2="69" WEIGHT="100.0" Z="1.457146924014169">
<NAME>1mg dose weekly for 4 weeks</NAME>
<CONT_DATA CI_END="0.5521113098363126" CI_START="-3.752111309836313" EFFECT_SIZE="-1.6" ESTIMABLE="YES" MEAN_1="-1.8" MEAN_2="-0.2" ORDER="104589" SD_1="5.9" SD_2="6.8" SE="1.09803615107823" STUDY_ID="STD-Hvas-2004" TOTAL_1="65" TOTAL_2="69" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-01" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION/>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAiYAAAGQCAIAAAAV1zzkAABzgUlEQVR42uydd1wUx///P7HFXrFX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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>